Nautilus Biotech and HanAll Pharmaceutical announce license agreement to develop three Nautilus Biotech products in South Korea
Nautilus Biotech announced the signing of a collaboration and license agreement with HanAll Pharmaceutical to develop and commercialize three Nautilus Biotech products in South Korea: Belerofon® (interferon alpha); Vitatropin® (human growth hormone); and Eporal(TM) (erythropoietin).
The agreement with HanAll Pharmaceuticals is limited to the territory of South Korea; Nautilus Biotech will continue to pursue the clinical development of these products in the USA as part of the Company's strategy for global commercialisation of these products.
Nautilus Biotech's novel technology makes minimal and specific changes to the amino acid sequence in order to slow the breakdown of the protein in the body, in blood, tissues or intestine. The three Nautilus Biotech proprietary proteins included in the agreement have been designed for extended half-life and oral availability. By reducing the number and frequency of treatments needed and offering oral administration, these new drugs will enhance patient convenience and compliance.
The three products that come under the license agreement include Belerofon, Nautilus Biotech's long-lasting human Interferon alpha, which has therapeutic potential for a number of conditions, including chronic Hepatitis C (HCV). Nautilus Biotech submitted an Investigational New Drug (IND) filing for oral Belerofon last month, following its submission in October 2006 for an IND filing for injectable Belerofon. . The license agreement with HanAll Pharmaceutical includes Vitatropin, Nautilus Biotech's proprietary variant of human growth hormone (hGH), for the treatment of children and adults with growth disorders. hGH is currently only available in injectable form and is normally administered daily.
Nautilus Biotech's agreement with HanAll Pharmaceutical also includes the development and commercialisation in South Korea of Eporal, an orally available version of the hormone erythropoietin, which stimulates the body to produce more red blood cells and is used in the treatment of anaemia.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Is surgery the only option for meniscal tear and osteoarthritis? - New research finds that for a number of patients physical therapy provides similar improvements in physical function and pain

Machine learning improves biological image analysis - International team of researchers develops algorithm that accelerates super-resolution microscopy

Unexpectedly potent protein droplets - Researchers discover new pathomechanism of hereditary diseases in cell condensates

How Molecular Chaperones Dissolve Protein Aggregates Linked To Parkinson’s Disease - Researchers unravel the mechanism of amyloid fibril disaggregation
Apotex Inc. Acquires Topgen E.S.V. in Belgium from Zambon

Unraveling key determinant of successful therapeutic vaccination against chronic hepatitis B
Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma

Optek-Danulat GmbH - Essen, Germany

Unique nasal microbiome

Antibodies from llamas could help in fight against COVID-19 - Scientists were inspired by antibodies produced by a llama named Winter

The first kobuviruses described from Africa
